Scilex Holding's (SCLX) Scilex Bio venture with IPMC said Wednesday it is enrolling patients with Alzheimer's disease showing mild cognitive impairment and mild dementia in the phase 2 study of KDS2010.
The company is currently enrolling 114 subjects in South Korea and enrollment of the US cohort will begin in 2025, Scilex Bio said.
Scilex Bio said it will evaluate the safety and efficacy of the drug in the randomized, double-blind, placebo-controlled study.
IPMC is a representative company of the Bio Innovation Consortium, which holds exclusive rights to NeuroBiogen's KDS2010 global license.
Price: 0.56, Change: -0.01, Percent Change: -2.59
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。